HBW Advisory Services LLC Invests $257,000 in Novo Nordisk A/S (NYSE:NVO)

HBW Advisory Services LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, Holdings Channel reports. The fund acquired 1,799 shares of the company’s stock, valued at approximately $257,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Novo Nordisk A/S by 38.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after purchasing an additional 26,067 shares during the last quarter. McKinley Carter Wealth Services Inc. raised its position in Novo Nordisk A/S by 37.0% in the 4th quarter. McKinley Carter Wealth Services Inc. now owns 60,356 shares of the company’s stock valued at $6,244,000 after purchasing an additional 16,293 shares during the last quarter. Harbour Trust & Investment Management Co purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $6,105,000. Bank of New Hampshire raised its position in Novo Nordisk A/S by 1,356.8% in the 1st quarter. Bank of New Hampshire now owns 13,257 shares of the company’s stock valued at $1,702,000 after purchasing an additional 12,347 shares during the last quarter. Finally, Cim LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $23,547,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $4.11 on Tuesday, reaching $130.11. 6,988,022 shares of the company were exchanged, compared to its average volume of 4,429,566. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 1-year low of $79.65 and a 1-year high of $148.15. The firm has a market cap of $583.87 billion, a price-to-earnings ratio of 45.07, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41. The company has a 50-day moving average of $138.01 and a 200-day moving average of $129.49.

Analyst Ratings Changes

Several analysts recently commented on NVO shares. BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Argus boosted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.